Actinium Pharmaceuticals (NYSE:ATNM) & Athersys (NASDAQ:ATHX) Head to Head Contrast

Actinium Pharmaceuticals (NYSE:ATNM) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and Athersys”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	N/A	N/A	-$48.82 million	($1.31)	-1.09
Athersys	$146,000.00	0.00	-$72.53 million	($2.03)	N/A

Actinium Pharmaceuticals has higher earnings, but lower revenue than Athersys. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Actinium Pharmaceuticals and Athersys, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0	0	2	0	3.00
Athersys	0	0	0	0	0.00

Actinium Pharmaceuticals presently has a consensus price target of $4.50, indicating a potential upside of 214.69%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Actinium Pharmaceuticals is more favorable than Athersys.

Institutional & Insider Ownership

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Actinium Pharmaceuticals and Athersys’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Athersys	N/A	N/A	-223.03%

Risk & Volatility

Actinium Pharmaceuticals has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the S&P 500.

Summary

Actinium Pharmaceuticals beats Athersys on 9 of the 12 factors compared between the two stocks.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

About Athersys

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.